ICTM logo

Cancer affects more than 14 million people worldwide each year and is a leading cause of death in adults in the UK. As the population ages, the incidence of many cancers is increasing, but the number of people living with cancer also continues to increase. In the UK the survival rate overall has now improved to over 50%.

This is because of improvements in treatments, which prolong people's lives, and because some cancers are being detected earlier, as a result of screening.

There have been some major advances in the treatment of cancer in the past 20 years. These are built upon multiple modest improvements in treatment and detection, which become clear when they are tested in randomised clinical trials. These trials are the main focus of the MRC CTU at UCL.


Useful links:

Cancer Research UK

The Institute of Cancer Research

International Agency for Research on Cancer

CANCER RESEARCH AT THE MRC CTU at UCL


The majority of our work in cancer involves the design, conduct and analysis of clinical trials, covering many different types of cancer. Most of our trials are large randomised controlled trials, which compare two or more treatments including chemotherapy, radiotherapy, biological agents, surgery or combinations of these. In some trials, we also test new diagnostic strategies or non-therapeutic approaches such as different follow-up policies.

Our trials compare treatments by looking at survival, return of disease, side effects and quality of life.

We also work closely with the Unit's meta-analysis group

Our research strategy in the coming years:

Our particular strengths lie in developing innovative clinical trials which sometimes relate to specific types of cancer but often can be applied more broadly. Our current and future research can broadly be classified into three main programmes:


1. Speeding up therapeutic evaluation by implementing new trial designs and methodology

2. Stratified medicine and translational science within large scale randomised trials

3. Trials that are particularly challenging or which have potential global reach

chemotherapy sign

LATEST NEWS

14 June 2017

The ICON6 trial team have released updated results suggesting that adding the drug cediranib to chemotherapy may improve survival for women with recurrent ovarian cancer. These results were presented on Friday 2 June at the American Society for Clinical Oncology (ASCO) conference in Chicago.

Read more


FEATURED STUDY

ICON8B

A phase 3 randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer


Read more

RECENT PUBLICATIONS

Ledermann, J.A., Embleton, A.C., Raja, F., Perren, T.J., Jayson, G.C., Rustin, G.J., Kaye, S.B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M., Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A.M., Cook, A., Kaplan, R.S., Parmar, M.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 387:1066-1074-1066-1074


More Publications